Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹æ±¤¾Ï ȯÀÚ¿¡¼­ Telomerase PCR-ELISA °Ë»ç¹ý Telomerase PCR-ELISA Assay In Diagnosis of Bladder Tumor

´ëÇѺñ´¢±â°úÇÐȸÁö 1999³â 40±Ç 3È£ p.322 ~ 326
ÁÖ±¤·Î, ±èÀ±È­, ³ª´ö±â,
¼Ò¼Ó »ó¼¼Á¤º¸
ÁÖ±¤·Î (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

±èÀ±È­ (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
³ª´ö±â (  ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ÀÓ»óº´¸®Çб³½Ç

Abstract

¼­·Ð
telomere´Â ¿°»öüÀÇ ³¡¿¡ À§Ä¡ÇÏ¿© ¿°»öüÀÇ À߸øµÈ À¶ÇÕÀ̳ª ºÐÇظ¦ ¸·¾Æ À¯ÀüÀÚ Á¤º¸
¸¦ À¯ÁöÇϴµ¥ Áß¿äÇÑ ¿ªÈ°À» ÇÑ´Ù. telomere´Â 5-15 kilobaseÀÇ Å©±â¸¦ °¡Áö°í ÀÖÀ¸¸ç ü¼¼
Æ÷¿¡¼­ °¨¼ö ºÐ¿­À» ÇÒ ¶§¸¶´Ù 50-200 base°¡ °¨¼ÒÇÏ¿©, Á¾±¹¿¡´Â telomere°¡ ºÎÁ·ÇÑ Ã¼¼¼
Æ÷´Â Á×À½¿¡ À̸£°Ô µÈ´Ù. ±×·¯³ª ¹è¾Æ¼¼Æ÷³ª Á¾¾ç¼¼Æ÷ °°Àº ºÒ¸ê¼¼Æ÷¿¡¼­´Â telomereÀÇ ±æ
À̸¦ ±æ°Ô ÇÏ´Â ¸®º¸ÇÙ»ê´Ü¹éÁúÀÎ telomerase°¡ È°¼ºÈ­µÇ¾î telomereÀÇ ±æÀÌ°¡ ¼¼Æ÷ ºÐ¿­°ú
°ü°è¾øÀÌ À¯ÁöµÈ´Ù. ±×¸®°í ¹æ±¤¾ÏÀ» Æ÷ÇÔÇÑ ´ëºÎºÐÀÇ ¾Ç¼ºÁ¾¾ç¿¡¼­ telomerase°¡ ¹ß°ßµÇ¸ç
ÀÌ È¿¼ÒÀÇ °ËÃâÀ» ÀÌ¿ëÇÏ¿© Á¾¾çÀÇ Áø´Ü, ÃßÀû°Ë»ç ¹× ¼±º°°Ë»ç¿¡ À¯¿ëÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ´Â
Á¾¾çÁöÇ¥·Î¼­ Á¦½ÃµÇ°í ÀÖ´Ù. telemerase¸¦ »ý¼ºÇÏ´Â ¼¼Æ÷°¡ ÀûÀº °æ¿ì(1-10°³)¿¡µµ
telomerase activity¸¦ ¹Î°¨ÇÏ°Ô ÇÏ´Â telomeric repeat amplification protocol(TRAP)ÀÌ °³¹ß
µÇ¾î ´Ù¾çÇÑ ¾Ç¼ºÁ¾¾çÀ» Áø´ÜÇϴµ¥ telemerase activity¸¦ ÃøÁ¤ÇÏ´Â ¹æ¹ýÀÌ ³Î¸® ÀÌ¿ëµÇ°Ô
µÇ¾ú´Ù. ¹æ±¤¾Ï¿¡¼­µµ ¸¶Âù°¡Áö·Î ºñħ½ÀÀûÀÎ Áø´Ü¹ýÀ¸·Î ¿äÁß¿¡¼­ telomeiase activity¸¦ Ãø
Á¤ÇÏ¿© ÁÁÀº °á°ú¸¦ º¸°íÇÏ°í ÀÖ´Ù. ±×·¯³ª Áö±Ý±îÁö º¸°íµÈ ´ëºÎºÐÀÇ °Ë»ç¹æ¹ýµéÀº Àü±â¿µ
µ¿À» ÇØ¾ß ÇÏ°í ¶ÇÇÑ ¹æ»ç¼±µ¿À§¿ø¼Ò¸¦ Çϱ⠶§¹®¿¡ ½ÇÁ¦ ÀÓ»ó¿¡¼­ ½ÃÇàÇϱ⿡´Â ¾î·Á¿î ÀÖ
´Ù. µû¶ó¼­ ÀúÀÚµéÀº ¹æ±¤¾Ï ȯÀÚÀÇ ¼¼Ã´´¢¸¦ äÃëÇÏ¿© telomeric repeat amplification ÈÄ
telomerase activity¸¦ È¿¼Ò¸é¿ªÃøÁ¤ ÇÏ´Â Æí¸® ÇÑ ¹æ¹ýÀ¸·Î telomerase activity¸¦ ÃøÁ¤ÇÏ¿©
µ¿ÀÏ È¯ÀÚ±º¿¡¼­ ½ÃÇàÇÑ ¿ä¼¼Æ÷°Ë»çÀÇ °á°ú¿Í ºñ±³ Æò°¡ÇÏ¿© telomerase PCR-ELISA °Ë»ç
¹ýÀÇ À¯¿ë¼ºÀ» Æò°¡ÇÏ¿´´Ù.

Purpose: The detection of telomerase activity is a new and useful method in diagnosis
of bladder transitional cell carcinoma(TCC) in urine samples. But the detection method
of telomerase activity is not easily performed in clinical settings because it uses
radio-isotope and electrophoresis. We evaluated the test results of telomerase
PCR-ELISA and compared them with the results of urinary cytology.
Materials and Methods: In order to evaluate the feasibility of telomerase PCR-ELISA
method in bladder TCC, 36 bladder washing samples of patients with bladder TCC and
10 bladder washing samples of benign urologic diseases were examined for telomerase
activity.
Results: The overall sensitivity and specificity of the telomerase test was 76.5%
(26/36) and 80.0%(4/5). The sensitivity of telomerase test was higher than that of
urinary cytology in low grade bladder TCC. Sensitivity of the telomerase test according
to the nuclear grade of bladder TCC was 61.5% in grade ¥°, 92.3% in grade ¥±, 75% in
grade ¥². In contrast, the sensitivity was 38.5% in grade ¥°, 66.7% in grade ¥±, 87.5%
in grade ¥² in urinary cytology. There was no correlation between the tumor stages and
the sensitivity of telomerase test.
Conclusions: We have shown that the sensitivity and specificity of telomerase
PCR-ELISA method is similar to the results of telomerase tests previously reported
using radioisotope. Furthermore, the telomerase test is more sensitive in detecting
bladder tumor of low grade than urinary cytology. These findings suggest that
telomerase PCR-ELISA method can be used conveniently and widely for the detection of
bladder tumor in clinical practice.

Å°¿öµå

Bladder tumor; Diagnostic marker; Telomerase activity; PCR-ELISA assay;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS